Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...

(MENAFN- GlobeNewsWire - Nasdaq) MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines ...

Europe to review safety data for Eisai-Biogen Alzheimer's drug January 31, 2025 Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy ...

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.